Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Fineline Cube Apr 13, 2026
Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026
Company Deals

Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally

Fineline Cube Feb 1, 2024

Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

Fineline Cube Feb 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...

Company Medical Device

Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment

Fineline Cube Feb 1, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Drug

Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons

Fineline Cube Feb 1, 2024

Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...

Company

WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry

Fineline Cube Feb 1, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...

Company

GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion

Fineline Cube Feb 1, 2024

GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...

Company

Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...

Company Drug

Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval

Fineline Cube Feb 1, 2024

Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...

Company Deals

Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience

Fineline Cube Feb 1, 2024

Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...

Company Deals

Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens

Fineline Cube Feb 1, 2024

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...

Company Deals

Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal

Fineline Cube Feb 1, 2024

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...

Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies

Fineline Cube Feb 1, 2024

MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...

Company Drug

Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri

Fineline Cube Feb 1, 2024

Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...

Company Deals R&D

Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse

Fineline Cube Jan 31, 2024

Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...

Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Company Drug

European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 31, 2024

The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...

Company Deals

WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies

Fineline Cube Jan 31, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company

Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs

Fineline Cube Jan 31, 2024

The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...

Company

Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products

Fineline Cube Jan 31, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Posts pagination

1 … 389 390 391 … 649

Recent updates

  • CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
  • Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
  • Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.